Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Cancer and Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a highly selective, orally active multi-target tyrosine kinase inhibitor (TKI) with sub-nanomolar inhibitory potency against VEGFR2, PDGFRβ, and FGFR1 (Xie et al., 2018). It exhibits potent anti-angiogenic effects, suppressing endothelial cell migration and capillary tube formation in vitro in a concentration-dependent manner. The compound shows high oral bioavailability and distributes to relevant tissues, including tumors and the central nervous system. Compared to agents like sunitinib or sorafenib, anlotinib demonstrates superior selectivity and efficacy in preclinical models. APExBIO supplies anlotinib hydrochloride (SKU C8688) as a research-grade reagent, enabling robust and reproducible experimental designs (APExBIO).

Biological Rationale

Angiogenesis is essential for tumor growth, invasion, and metastatic progression. The process relies on the proliferation, migration, and tube formation of vascular endothelial cells, events orchestrated by key growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) (Xie et al., 2018). Among these, VEGF/VEGFR2 signaling is pivotal in neovascularization and is a validated target in anti-cancer drug development. Inhibiting these pathways can effectively suppress tumor vascularization and limit cancer progression. Multi-target TKIs such as anlotinib address redundancy and compensatory mechanisms in tumor angiogenesis that often limit the efficacy of single-target agents.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a novel, small-molecule inhibitor that binds the ATP-binding pocket of VEGFR2, PDGFRβ, and FGFR1 tyrosine kinases. The inhibition constants are IC₅₀ = 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1. Anlotinib blocks downstream ERK signaling, suppressing cell proliferation and migration. In endothelial cell assays (EA.hy 926, HUVEC), anlotinib inhibits VEGF/PDGF-BB/FGF2-induced migration and tube formation in a dose-dependent manner (Xie et al., 2018). The compound shows higher selectivity and potency than reference TKIs, including sunitinib, sorafenib, and nintedanib.

Evidence & Benchmarks

• Anlotinib exhibits sub-nanomolar IC₅₀ values for VEGFR2 inhibition in kinase assays (Xie 2018, DOI).
• In cellular models, anlotinib blocks VEGF-induced HUVEC proliferation and tube formation at picomolar to nanomolar concentrations (Xie 2018, DOI).
• In vivo, anlotinib reduces tumor vascular density and induces tumor regression in nude mouse xenografts at once-daily oral dosing (Xie 2018, DOI).
• Pharmacokinetic studies show oral bioavailability of 28–58% in rats and 41–77% in dogs, with high tissue penetration and 93% plasma protein binding in humans (APExBIO).
• Compared to sunitinib or sorafenib, anlotinib demonstrates broader target inhibition and superior anti-angiogenic efficacy (mek12.com).

For further mechanistic depth, see this article, which provides an extended analysis of pathway integration. The present article updates that coverage with new pharmacokinetic and safety findings.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is primarily intended for research applications, especially in studies of tumor angiogenesis, endothelial cell migration, and tyrosine kinase signaling pathway modulation. Its use in cell-based assays (e.g., EA.hy 926, HUVEC lines) allows for precise dissection of anti-angiogenic mechanisms. The compound is also applied in in vivo models for evaluation of tumor vascularization and regression. APExBIO supplies anlotinib strictly for research use; it is not approved for diagnostic or therapeutic applications in humans or animals (APExBIO).

Common Pitfalls or Misconceptions

• Anlotinib is not suitable for direct clinical or diagnostic use; it is a research-use-only reagent.
• Direct anti-tumor proliferation effects in vitro require higher concentrations (micromolar range) than those needed for anti-angiogenic assays (Xie et al., 2018).
• Results in rodent models may not directly translate to human clinical outcomes due to interspecies differences in pharmacokinetics.
• Off-target effects outside VEGFR2, PDGFRβ, and FGFR1 are minimal but not entirely excluded at very high concentrations.
• Long-term storage requires -20°C; repeated freeze-thaw cycles may degrade compound activity (see product documentation).

Workflow Integration & Parameters

Anlotinib hydrochloride (SKU C8688) is supplied as a stable, lyophilized powder by APExBIO. For in vitro assays, the compound should be dissolved in DMSO to a stock concentration (e.g., 10 mM), then diluted into assay buffers. Standard working concentrations range from 1 nM to 10 μM, depending on endpoint and cell type. For in vivo mouse models, oral administration by gavage is typical, with dosing regimens based on published pharmacokinetic and safety data (e.g., LD₅₀ = 1735.9 mg/kg over 14 days in rodents). Tissue distribution studies confirm high accumulation in lung, liver, kidney, heart, and tumor, as well as blood-brain barrier penetration. For a practical integration guide, see this resource, which this article extends by including updated safety and metabolism data.

For benchmarking against other multi-target TKIs and extended mechanistic insight, see the systems-level analysis at this article. Here, we further clarify its distinct pharmacokinetic advantages and tissue distribution profile.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, high-potency multi-target tyrosine kinase inhibitor for angiogenesis and cancer research. Its selectivity, oral bioavailability, and robust anti-angiogenic properties make it a superior choice for preclinical studies. As research advances, anlotinib's contribution to anti-angiogenic drug discovery and tumor biology will expand, especially with ongoing efforts to map resistance and translational relevance. Researchers are encouraged to reference the APExBIO product page for full technical specifications and handling protocols.